Skip to main content

PrabotulinumtoxinA Disease Interactions

There are 4 disease interactions with prabotulinumtoxinA.

Major

PrabotulinumtoxinA (applies to prabotulinumtoxinA) infections

Major Potential Hazard, Moderate plausibility. Applicable conditions: Infection - Bacterial/Fungal/Protozoal/Viral

The administration of prabotulinumtoxinA is contraindicated in the presence of infection at the proposed injection site(s).

References

  1. (2022) "Product Information. Jeuveau (prabotulinumtoxinA)." Evolus, Inc.
Moderate

PrabotulinumtoxinA (applies to prabotulinumtoxinA) cardiovascular toxicity

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Cardiovascular Disease, Heart Disease

The administration of prabotulinumtoxinA may cause cardiovascular adverse events, including arrhythmia and myocardial infarction, some with fatal outcomes. It is recommended to monitor and use caution when using this agent in patients with preexisting cardiovascular disease.

References

  1. (2022) "Product Information. Jeuveau (prabotulinumtoxinA)." Evolus, Inc.
Moderate

PrabotulinumtoxinA (applies to prabotulinumtoxinA) dysphagia/breathing

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Pulmonary Impairment

The administration of botulinum toxin products, including prabotulinumtoxinA can result in swallowing or breathing difficulties. Patients with preexisting swallowing or breathing difficulties may be more susceptible to these complications. Patients treated with botulinum toxin products may require immediate medical attention should they develop problems with swallowing, speech or breathing. These reactions can occur within hours to weeks after injection with botulinum toxin. Caution is recommended when using this agent in patients at risk.

References

  1. (2022) "Product Information. Jeuveau (prabotulinumtoxinA)." Evolus, Inc.
Moderate

PrabotulinumtoxinA (applies to prabotulinumtoxinA) neuromuscular disorders

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Peripheral Neuropathy, Myasthenia Gravis

The administration of prabotulinumtoxinA to patients with preexisting neuromuscular disorders may increase the risk of clinically significant effects, including generalized muscle weakness, diplopia, ptosis, dysphonia, dysarthria, severe dysphagia and respiratory compromise. Exercise care when using this agent in patients at risk.

References

  1. (2022) "Product Information. Jeuveau (prabotulinumtoxinA)." Evolus, Inc.

PrabotulinumtoxinA drug interactions

There are 119 drug interactions with prabotulinumtoxinA.

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer